Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

dc.creatorMahil, Satveer K.
dc.creatorDand, Nick
dc.creatorMason, Kayleigh J.
dc.creatorYiu, Zenas ZN.
dc.creatorTsakok, Teresa
dc.creatorMeynell, Freya
dc.creatorCoker, Bola
dc.creatorMcAteer, Helen
dc.creatorMoorhead, Lucy
dc.creatorMackenzie, Teena
dc.creatorRossi, Maria Teresa
dc.creatorRivera, Raquel
dc.creatorMahe, Emmanuel
dc.creatorCarugno, Andrea
dc.creatorMagnano, Michela
dc.creatorRech, Giulia
dc.creatorBalogh, Esther A.
dc.creatorFeldman, Steven R.
dc.creatorCruz, Claudia De La
dc.creatorChoon, Siew Eng
dc.creatorNaldi, Luigi
dc.creatorLambert, Jo
dc.creatorSpuls, Phyllis
dc.creatorJullien, Denis
dc.creatorBachelez, Hervé
dc.creatorMcMahon, Devon E.
dc.creatorFreeman, Esther E.
dc.creatorGisondi, Paolo
dc.creatorPuig, Luis
dc.creatorWarren, Richard B.
dc.creatorMeglio, Paola Di
dc.creatorLangan, Sinéad M.
dc.creatorCapon, Francesca
dc.creatorGriffiths, Christopher EM.
dc.creatorFMedSci, MD
dc.creatorBarker, Jonathan N.
dc.creatorSmith, Catherine H.
dc.date.accessioned2020-10-22T17:45:26Z
dc.date.available2020-10-22T17:45:26Z
dc.date.created2020
dc.description.abstractBackground: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. Objective: Characterize the course of COVID-19 in psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an international registry, PsoProtect. Multiple logistic regression assessed the association between clinical/demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviours. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24- 8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% CI 1.31-6.18). No significant differences were found between biologic classes. Independent patient-reported data (n=1,626 across 48 countries) suggested lower levels of social isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 0.68, 95% CI 0.50-0.94). Conclusion: In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, comorbidities) were associated with higher hospitalization rates.spa
dc.format.extent34 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.jaci.2020.10.007spa
dc.identifier.issn0091-6749spa
dc.identifier.otherhttps://doi.org/10.1016/j.jaci.2020.10.007spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/14764
dc.language.isoengspa
dc.publisherJournal of Allergy and Clinical Immunologyspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectHospitalizationspa
dc.subjectPsoriasisspa
dc.subjectRisk factorsspa
dc.subjectBiologicsspa
dc.subjectMmunosuppressantsspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleFactors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based studyspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: